血清β-2微球蛋白测定在恶性血液病中的临床意义  

The Clinical Significance of the Determination of Serum β_2-microglobulin in Malignant Blood Diseases

作　　者：熊树民[1] 颜纪贤[1] 李海棠[1] 沈国勇[1] 谢亦英 孙文辉[2] 华铮[2] 成也宽[2] 

机构地区：[1]上海第二医科大学宝钢医院上海血液学研究所 [2]江苏省常州市第一人民医院

出　　处：《临床血液学杂志》1989年第3期113-114,共2页Journal of Clinical Hematology

摘　　要：95例急,慢性白血病,非何杰金淋巴瘤(NHL)和多发性骨髓瘤(MM)的S-β_2m水平在发病期和复发期均明显增高(P<0.001),在缓解期均恢复正常(P>0.05).故S-β_2m可作为观察疗效和判断预后的辅助指标。The β_2-microglobulin level was measured in 95 cases of acute leukemia, chronic leukemia. non-Hodgkins' lymphoma and multiple myeloma. The mean value of β_2-microglobulin was increased significantly (P<0.001) in. untraeted patients and in relapse.It returned to normal level during remission. It was suggested that the determination of β_2-microglobulin provides a reliable means lor monitoring the response to treatment and prognosis.

关 键 词：恶性血液病 慢性白血病 多发性骨髓瘤 非何杰金淋巴瘤 微球蛋白 辅助指标 发病期 献血员 淋巴瘤患者 尿酸代谢 

分 类 号：R55[医药卫生—血液循环系统疾病]